Comparative Pharmacology
Head-to-head clinical analysis: MYCOBUTIN versus PYRAZINAMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MYCOBUTIN versus PYRAZINAMIDE.
MYCOBUTIN vs PYRAZINAMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits DNA-dependent RNA polymerase in Mycobacterium tuberculosis, blocking RNA synthesis.
Converted to pyrazinoic acid, which disrupts membrane potential and inhibits mycobacterial fatty acid synthase (FAS-1).
300 mg orally once daily, or 300 mg twice weekly for MAC prophylaxis in HIV. For TB, 300 mg daily as part of combination therapy.
15-30 mg/kg orally once daily (max 2 g/day) for initial phase of tuberculosis treatment.
None Documented
None Documented
Terminal elimination half-life: 35-40 hours (range 30-50 hours). Clinical context: Allows once-daily dosing; prolonged in hepatic or renal impairment.
Clinical Note
moderatePyrazinamide + Tenofovir disoproxil
"The metabolism of Tenofovir disoproxil can be decreased when combined with Pyrazinamide."
Clinical Note
moderatePyrazinamide + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Pyrazinamide."
Clinical Note
moderatePyrazinamide + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Pyrazinamide."
Clinical Note
moderatePyrazinamide + Fluconazole
9–10 hours in patients with normal renal function; prolonged to 15–20 hours in renal impairment; requires dose adjustment in renal failure
Renal (30% as unchanged drug), fecal (50-60% as metabolites and parent compound), biliary (minor).
Renal: approximately 70% (40% unchanged, 30% as metabolites); biliary/fecal: minimal (less than 10%)
Category C
Category A/B
Antimycobacterial
Antimycobacterial
"The metabolism of Fluconazole can be decreased when combined with Pyrazinamide."